ICU Medical (NASDAQ:ICUI) was downgraded by research analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a note issued to investors on Thursday, September 20th.
Several other research firms also recently issued reports on ICUI. ValuEngine downgraded ICU Medical from a “strong-buy” rating to a “buy” rating in a report on Friday, August 3rd. Zacks Investment Research upgraded ICU Medical from a “hold” rating to a “strong-buy” rating and set a $337.00 price objective on the stock in a report on Wednesday, August 15th. Finally, TheStreet upgraded ICU Medical from a “c+” rating to a “b+” rating in a report on Monday, August 20th. One equities research analyst has rated the stock with a hold rating and two have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $337.00.
Shares of NASDAQ:ICUI traded up $4.95 during trading on Thursday, reaching $265.80. The stock had a trading volume of 167,031 shares, compared to its average volume of 157,986. ICU Medical has a 1-year low of $180.45 and a 1-year high of $321.70. The firm has a market capitalization of $5.79 billion, a PE ratio of 48.15 and a beta of 0.41.
ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings data on Thursday, August 9th. The medical instruments supplier reported $2.66 EPS for the quarter, topping the Zacks’ consensus estimate of $1.82 by $0.84. ICU Medical had a return on equity of 12.78% and a net margin of 5.93%. The firm had revenue of $360.46 million for the quarter, compared to the consensus estimate of $337.60 million. During the same quarter last year, the business posted $0.76 earnings per share. The firm’s revenue was up 8.7% compared to the same quarter last year. On average, analysts forecast that ICU Medical will post 7.6 earnings per share for the current year.
In related news, Director Pfizer Inc sold 700,000 shares of the business’s stock in a transaction on Monday, August 13th. The stock was sold at an average price of $284.35, for a total transaction of $199,045,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Virginia Ruth Sanzone sold 787 shares of the business’s stock in a transaction on Tuesday, August 28th. The stock was sold at an average price of $303.12, for a total value of $238,555.44. Following the transaction, the vice president now directly owns 1,367 shares of the company’s stock, valued at $414,365.04. The disclosure for this sale can be found here. Insiders have sold a total of 711,920 shares of company stock valued at $202,651,956 over the last three months. 12.50% of the stock is currently owned by insiders.
Several large investors have recently added to or reduced their stakes in ICUI. Cerebellum GP LLC acquired a new position in shares of ICU Medical during the 3rd quarter worth about $186,000. Mackay Shields LLC acquired a new position in shares of ICU Medical during the 2nd quarter worth about $205,000. CIBC Asset Management Inc acquired a new position in shares of ICU Medical during the 2nd quarter worth about $209,000. LPL Financial LLC purchased a new stake in shares of ICU Medical in the 1st quarter valued at about $218,000. Finally, Campbell & CO Investment Adviser LLC purchased a new stake in shares of ICU Medical in the 2nd quarter valued at about $230,000. 74.29% of the stock is owned by institutional investors and hedge funds.
ICU Medical Company Profile
ICU Medical, Inc develops, manufactures, and sells medical devices used in vascular therapy, critical care, and oncology applications worldwide. It offers infusion therapy products comprising a tube running from a bottle or plastic bag containing a solution to a catheter inserted in a patient's vein.
Featured Story: Exchange-Traded Funds (ETFs)
Receive News & Ratings for ICU Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical and related companies with MarketBeat.com's FREE daily email newsletter.